Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Farabursen - Novartis

Next Previous
Drug Profile

Farabursen - Novartis

Alternative Names: RGLS-8429

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regulus Therapeutics
  • Developer Novartis
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action Gene silencing; MIRN17 microRNA expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal dominant polycystic kidney disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autosomal dominant polycystic kidney disease

Most Recent Events

  • 25 Jun 2025 Regulus Therapeutics has been acquired and merged into Novartis
  • 08 May 2025 Regulus Therapeutics completes a phase I trial in Autosomal dominant polycystic kidney disease in USA (SC) before May 2025 (NCT05521191)
  • 27 Mar 2025 Regulus Therapeutics plans a pivotal phase III trial in Autosomal dominant polycystic kidney disease in the third quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top